JP:4507 Stock Latest News
Company AnnouncementsShionogi Corrects Earnings and Dividend Forecast Disclosure Without Changing Results2d ago
Company AnnouncementsShionogi Raises Interim Dividend on Stronger Earnings and Cash Generation3d ago
Company AnnouncementsShionogi’s First-Half Earnings Surge on Acquisitions and Overseas Growth3d ago
Company AnnouncementsShionogi boosts dividend and upgrades full-year outlook on sharp profit surge3d ago
Company AnnouncementsShionogi Lifts Earnings Outlook and Boosts Dividends on Strong Growth Investments3d ago
Company AnnouncementsShionogi to Buy IntraBio for $2 Billion, Bolstering Rare Disease Portfolio3w agoCompany AnnouncementsShionogi Wins Pediatric Approval for VTAMA Atopic Dermatitis Cream in Japan1M ago
Company AnnouncementsShionogi Wins Japan Approval for JN.1 COVID Booster, Advances Vaccine Platform1M ago
Company AnnouncementsShionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth3M ago
Company AnnouncementsShionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact3M ago
Pre-EarningsSGIOF Earnings this Week: How Will it Perform?3M ago
Company AnnouncementsShionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan3M ago
Company AnnouncementsShionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan4M agoCompany AnnouncementsShionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices4M ago
- Company AnnouncementsShionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim4M ago
- Company AnnouncementsShionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic5M ago
- Company AnnouncementsShionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug5M ago
Company AnnouncementsShionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation5M agoCompany AnnouncementsShionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY20265M ago
